Hepatotoxicity of statins and other lipid‐lowering agents
Statins are generally well tolerated and adverse effects are relatively rare. Clinical trials are underpowered to detect uncommon adverse effects such as idiosyncratic drug‐induced liver injury. This review is aimed at covering the current knowledge on the hepatotoxicity associated with statins and...
Saved in:
| Published in | Liver international Vol. 37; no. 2; pp. 173 - 178 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.02.2017
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Statins are generally well tolerated and adverse effects are relatively rare. Clinical trials are underpowered to detect uncommon adverse effects such as idiosyncratic drug‐induced liver injury. This review is aimed at covering the current knowledge on the hepatotoxicity associated with statins and other lipid lowering drugs. Both atorvastatin and simvastatin have been associated with more than 50 case reports of liver injury and other statins have been implicated in this type of liver injury as well. Idiosyncratic liver injury due to statins has been reported to occur 1.9%‐5.5% of patients in prospective series of drug‐induced liver injury. Atorvastatin and simvastatin have been associated with positive rechallenge and some case reports have described liver injury following dose escalation of the implicated statin. Mortality from liver injury and/or liver transplantation has been documented in a few patients with statin induced liver injury although the vast majority of patients with liver injury have recovered after cessation of therapy. |
|---|---|
| AbstractList | Statins are generally well tolerated and adverse effects are relatively rare. Clinical trials are underpowered to detect uncommon adverse effects such as idiosyncratic drug-induced liver injury. This review is aimed at covering the current knowledge on the hepatotoxicity associated with statins and other lipid lowering drugs. Both atorvastatin and simvastatin have been associated with more than 50 case reports of liver injury and other statins have been implicated in this type of liver injury as well. Idiosyncratic liver injury due to statins has been reported to occur 1.9%-5.5% of patients in prospective series of drug-induced liver injury. Atorvastatin and simvastatin have been associated with positive rechallenge and some case reports have described liver injury following dose escalation of the implicated statin. Mortality from liver injury and/or liver transplantation has been documented in a few patients with statin induced liver injury although the vast majority of patients with liver injury have recovered after cessation of therapy. Abstract Statins are generally well tolerated and adverse effects are relatively rare. Clinical trials are underpowered to detect uncommon adverse effects such as idiosyncratic drug‐induced liver injury. This review is aimed at covering the current knowledge on the hepatotoxicity associated with statins and other lipid lowering drugs. Both atorvastatin and simvastatin have been associated with more than 50 case reports of liver injury and other statins have been implicated in this type of liver injury as well. Idiosyncratic liver injury due to statins has been reported to occur 1.9%‐5.5% of patients in prospective series of drug‐induced liver injury. Atorvastatin and simvastatin have been associated with positive rechallenge and some case reports have described liver injury following dose escalation of the implicated statin. Mortality from liver injury and/or liver transplantation has been documented in a few patients with statin induced liver injury although the vast majority of patients with liver injury have recovered after cessation of therapy. |
| Author | Björnsson, Einar S. |
| Author_xml | – sequence: 1 givenname: Einar S surname: Bjornsson fullname: Bjornsson, Einar S |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27860156$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kLtOwzAUQC1URB8w8AMoEhNDWjuuY0dMqAJaqRILsFqO7RRXaRxsl5KNT-Ab-RICKd24y73D0bnSGYJeZSsNwDmCY9TOpDRvY4QxZEdggKaUxTjBqHe4E9wHQ-_XEKIsI-gE9BPKUohIOgDXc12LYIN9N9KEJrJF5IMIpvKRqFRkw4t2UWlqo74-Pku7085Uq0isdBX8KTguROn12X6PwNPd7eNsHi8f7hezm2UsMWMsZoIqKYWi7aEZEZRQSgjJJUwZYgJrleVQMpFPFS6gYlIWuEAYJhRRCEWCR-Cy89bOvm61D3xtt65qX3KUJZCgdEppS111lHTWe6cLXjuzEa7hCPKfTLzNxH8ztezF3rjNN1odyL8uLTDpgJ0pdfO_iS8Xz53yGy1gc8U |
| CitedBy_id | crossref_primary_10_1016_j_jhep_2021_01_024 crossref_primary_10_3138_canlivj_2023_0028 crossref_primary_10_1016_j_mad_2023_111805 crossref_primary_10_1016_j_envres_2023_116572 crossref_primary_10_14423_SMJ_0000000000000752 crossref_primary_10_1016_j_atherosclerosis_2019_02_028 crossref_primary_10_1007_s11033_021_06674_6 crossref_primary_10_1016_j_arabjc_2023_105486 crossref_primary_10_1016_j_nano_2023_102700 crossref_primary_10_1016_j_phymed_2022_153983 crossref_primary_10_1016_j_jmii_2024_04_002 crossref_primary_10_1002_cpt_2527 crossref_primary_10_1016_j_ijtb_2023_12_010 crossref_primary_10_1080_14740338_2020_1836153 crossref_primary_10_1146_annurev_med_042220_020407 crossref_primary_10_1002_cld_788 crossref_primary_10_1007_s40261_022_01202_1 crossref_primary_10_1007_s15036_020_0278_0 crossref_primary_10_1016_j_lfs_2021_119220 crossref_primary_10_1016_j_biopha_2021_111532 crossref_primary_10_1186_s12877_022_03087_3 crossref_primary_10_1002_iid3_1145 crossref_primary_10_4103_ejpi_EJPI_D_23_00031 crossref_primary_10_1016_j_fochms_2022_100092 crossref_primary_10_1080_17425255_2017_1362391 crossref_primary_10_1371_journal_pone_0205138 crossref_primary_10_1080_00498254_2023_2290648 crossref_primary_10_3390_molecules28073160 crossref_primary_10_30895_2312_7821_2023_389 crossref_primary_10_1038_s41598_022_16357_2 crossref_primary_10_3389_fmolb_2021_762673 crossref_primary_10_1038_s41401_021_00621_8 crossref_primary_10_1155_2019_1582183 crossref_primary_10_1161_CIRCRESAHA_118_312782 crossref_primary_10_1016_j_jfutfo_2023_03_003 crossref_primary_10_11648_j_ijg_20240801_16 crossref_primary_10_1080_14740338_2020_1796966 crossref_primary_10_56095_eaj_v1i3_20 crossref_primary_10_1152_ajpgi_00441_2016 crossref_primary_10_4068_cmj_2024_60_1_13 crossref_primary_10_2174_1570180816666181112144353 crossref_primary_10_1016_j_eujim_2019_100950 crossref_primary_10_1155_2020_9519736 crossref_primary_10_2147_IJGM_S460305 crossref_primary_10_1002_ddr_21581 crossref_primary_10_3390_nu16121954 crossref_primary_10_37939_jrmc_v27i1_2066 crossref_primary_10_1016_j_jhep_2021_06_021 crossref_primary_10_1136_gutjnl_2019_318237 crossref_primary_10_3350_cmh_2022_0186 crossref_primary_10_1007_s11938_022_00394_x crossref_primary_10_1038_s41598_021_81846_9 crossref_primary_10_1016_j_jfma_2024_04_003 crossref_primary_10_1016_j_toxlet_2022_08_006 crossref_primary_10_1039_D0BM00474J crossref_primary_10_1016_j_jceh_2022_07_240 crossref_primary_10_1016_j_hbpd_2022_10_004 crossref_primary_10_1139_cjpp_2017_0599 crossref_primary_10_17116_dokgastro20176147_55 crossref_primary_10_1016_j_biopha_2022_114075 crossref_primary_10_3390_ijms232415506 crossref_primary_10_1097_MEG_0000000000001719 crossref_primary_10_1016_j_cbi_2024_110956 crossref_primary_10_33667_2078_5631_2021_29_13_20 crossref_primary_10_1002_jcsm_12960 crossref_primary_10_1155_2020_9650619 crossref_primary_10_3390_ijms23169326 crossref_primary_10_1002_hep_32689 crossref_primary_10_1002_jcp_29756 crossref_primary_10_1007_s00784_023_05427_y crossref_primary_10_18087_cardio_2505 crossref_primary_10_1002_jat_3825 crossref_primary_10_2174_0113892010267577231005102901 crossref_primary_10_3389_fphar_2018_00685 crossref_primary_10_1038_s41401_022_00909_3 crossref_primary_10_1038_s41598_022_11027_9 crossref_primary_10_1002_term_2652 crossref_primary_10_1080_17474124_2018_1477588 crossref_primary_10_1097_HEP_0000000000000278 crossref_primary_10_1016_j_taap_2021_115557 crossref_primary_10_1016_j_bej_2020_107831 crossref_primary_10_1007_s11938_018_0180_4 crossref_primary_10_1016_j_jare_2023_02_007 crossref_primary_10_1016_j_biopha_2017_12_076 crossref_primary_10_1177_23247096211014050 crossref_primary_10_1016_j_jep_2023_117684 crossref_primary_10_1097_MD_0000000000033139 crossref_primary_10_1080_14740338_2020_1835045 crossref_primary_10_1016_j_sjbs_2021_07_045 crossref_primary_10_5937_mckg57_45647 crossref_primary_10_1007_s00296_021_05059_z crossref_primary_10_1111_bcp_14599 crossref_primary_10_1080_14740338_2020_1732921 crossref_primary_10_1093_cvr_cvac020 crossref_primary_10_14302_issn_2692_1537_ijcv_21_4053 crossref_primary_10_1016_j_transproceed_2024_05_015 crossref_primary_10_3389_fgene_2020_575678 crossref_primary_10_4103_jcpc_jcpc_8_22 crossref_primary_10_3389_fphar_2022_917521 crossref_primary_10_1515_jbcpp_2021_0013 crossref_primary_10_1097_MOG_0000000000000716 |
| Cites_doi | 10.1097/00042737-200308000-00014 10.1007/s10620-011-1950-1 10.1053/j.gastro.2008.09.011 10.1001/jama.285.13.1711 10.1001/archinte.159.15.1811-a 10.1016/j.jhep.2010.12.041 10.1016/j.cgh.2014.07.062 10.1016/S0168-8278(03)00464-1 10.1038/ajg.2010.287 10.1002/hep.20800 10.1046/j.1365-2796.2001.00848.x 10.1001/archinte.1991.00400010067008 10.1016/j.amjmed.2005.02.008 10.1002/hep.21848 10.1056/NEJM199511163332001 10.1097/00007611-198302000-00023 10.1097/MCG.0b013e3181c5e9cc 10.1002/hep.23937 10.1016/j.dld.2006.04.013 10.1002/hep.23317 10.1053/j.gastro.2013.02.006 10.1016/j.jhep.2011.07.023 10.1002/hep.21424 10.1001/jama.1959.63010170008010c 10.1053/j.gastro.2004.02.015 10.1002/lt.20204 10.1016/S0002-9343(02)01178-6 10.1056/NEJM197808102990622 10.1002/hep.26208 10.1002/hep.28323 10.1055/s-0029-1240010 10.1002/hep.22272 10.5694/j.1326-5377.2002.tb04559.x 10.1016/j.jhep.2014.11.019 10.1002/hep.27157 10.1097/00004836-200609000-00018 10.1001/jama.1974.03230270046027 10.1007/s40264-014-0182-7 10.5694/j.1326-5377.1991.tb116406.x 10.1016/j.gastro.2005.05.006 10.1016/S0140-6736(94)91755-8 10.1053/j.gastro.2015.03.006 10.1002/hep.23588 10.1016/j.jhep.2016.05.003 |
| ContentType | Journal Article |
| Copyright | 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. 2017 John Wiley & Sons A/S |
| Copyright_xml | – notice: 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd – notice: 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. – notice: 2017 John Wiley & Sons A/S |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QO 7T5 7U9 8FD FR3 H94 P64 RC3 |
| DOI | 10.1111/liv.13308 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Biotechnology Research Abstracts Immunology Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts Genetics Abstracts |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Genetics Abstracts Virology and AIDS Abstracts Biotechnology Research Abstracts Technology Research Database AIDS and Cancer Research Abstracts Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts |
| DatabaseTitleList | Genetics Abstracts CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1478-3231 |
| EndPage | 178 |
| ExternalDocumentID | 10_1111_liv_13308 27860156 LIV13308 |
| Genre | reviewArticle Journal Article Review |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 29L 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 ZXP ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QO 7T5 7U9 8FD FR3 H94 P64 RC3 |
| ID | FETCH-LOGICAL-c3888-8a7dccad78a7e85a7577555bc06818a3ed9b0c8ab4d3f0d8ccf3f130271700a23 |
| IEDL.DBID | DR2 |
| ISSN | 1478-3223 |
| IngestDate | Sat Aug 31 00:01:47 EDT 2024 Fri Aug 23 02:26:15 EDT 2024 Sat Sep 28 08:46:37 EDT 2024 Sat Aug 24 01:15:21 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | drug-induced liver injury simvastatin atorvastatin hepatotoxicity statins |
| Language | English |
| License | 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3888-8a7dccad78a7e85a7577555bc06818a3ed9b0c8ab4d3f0d8ccf3f130271700a23 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/liv.13308 |
| PMID | 27860156 |
| PQID | 1920516477 |
| PQPubID | 2045125 |
| PageCount | 6 |
| ParticipantIDs | proquest_journals_1920516477 crossref_primary_10_1111_liv_13308 pubmed_primary_27860156 wiley_primary_10_1111_liv_13308_LIV13308 |
| PublicationCentury | 2000 |
| PublicationDate | February 2017 2017-02-00 20170201 |
| PublicationDateYYYYMMDD | 2017-02-01 |
| PublicationDate_xml | – month: 02 year: 2017 text: February 2017 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Liver international |
| PublicationTitleAlternate | Liver Int |
| PublicationYear | 2017 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2015; 13 2004; 126 2001; 285 1991; 15 1991; 155 2015; 148 2002; 176 2010; 105 2002; 113 2006; 38 2005; 118 1991; 82 2013; 144 1983; 76 2005; 42 2003; 15 2011; 55 1974; 228 2003; 39 1995; 333 1978; 299 2012; 57 2012; 56 1998; 21 2014; 60 2009; 29 2004; 10 1959; 170 1994; 344 2010; 44 1998; 59 2014; 106 2013; 58 2001; 150 2006; 40 2015; 62 2006; 44 2005; 129 2008; 47 2014; 37 1999; 151 2016; 63 2008; 135 2005; 16 1999; 159 2010; 52 2007; 46 2010; 51 Bradford RH (e_1_2_11_3_1) 1999; 151 Ballare M (e_1_2_11_8_1) 1991; 82 Heyningen C (e_1_2_11_37_1) 2005; 16 e_1_2_11_32_1 e_1_2_11_30_1 e_1_2_11_36_1 e_1_2_11_51_1 e_1_2_11_13_1 e_1_2_11_34_1 e_1_2_11_11_1 e_1_2_11_29_1 e_1_2_11_6_1 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_48_1 e_1_2_11_2_1 e_1_2_11_45_1 e_1_2_11_24_1 e_1_2_11_41_1 Feydy P (e_1_2_11_7_1) 1991; 15 e_1_2_11_22_1 e_1_2_11_43_1 e_1_2_11_17_1 Rourk RM (e_1_2_11_47_1) 1998; 59 e_1_2_11_15_1 e_1_2_11_38_1 e_1_2_11_19_1 Perdices EV (e_1_2_11_20_1) 2014; 106 e_1_2_11_50_1 e_1_2_11_10_1 e_1_2_11_31_1 e_1_2_11_14_1 e_1_2_11_35_1 e_1_2_11_12_1 e_1_2_11_33_1 e_1_2_11_28_1 e_1_2_11_5_1 e_1_2_11_26_1 e_1_2_11_21_1 e_1_2_11_44_1 e_1_2_11_46_1 e_1_2_11_25_1 e_1_2_11_40_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_42_1 e_1_2_11_18_1 Bustamante Balén M (e_1_2_11_49_1) 1998; 21 e_1_2_11_16_1 e_1_2_11_39_1 |
| References_xml | – volume: 51 start-page: 615 year: 2010 end-page: 620 article-title: Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events publication-title: Hepatology – volume: 44 start-page: 128 year: 2010 end-page: 132 article-title: The characteristics and clinical outcome of drug‐induced liver injury: a single‐center experience publication-title: J Clin Gastroenterol – volume: 118 start-page: 618 year: 2005 end-page: 624 article-title: Evaluation of cases of severe statin‐related transaminitis within a large health maintenance organization publication-title: Am J Med – volume: 129 start-page: 512 year: 2005 end-page: 521 article-title: Drug‐induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10‐year period. Spanish Group for the Study of Drug‐Induced Liver Disease publication-title: Gastroenterology – volume: 176 start-page: 561 year: 2002 article-title: Cholestasis associated with the use of pravastatin sodium publication-title: Med J Aust – volume: 62 start-page: 739 year: 2015 end-page: 752 article-title: Acute liver failure following atorvastatin dose escalation: is there athreshold dose for idiosyncratic hepatotoxicity? publication-title: J Hepatol – volume: 159 start-page: 1811 year: 1999 end-page: 1812 article-title: Atorvastatin‐induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves publication-title: Arch Intern Med – volume: 285 start-page: 1711 year: 2001 end-page: 1718 article-title: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial publication-title: JAMA – volume: 55 start-page: 820 year: 2011 end-page: 827 article-title: Recurrent drug‐induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis publication-title: J Hepatol – volume: 63 start-page: 532 year: 2016 end-page: 542 article-title: Definition and risk factors for chronicity following acute idiosyncratic drug‐induced liver injury publication-title: J Hepatol – volume: 44 start-page: 1581 year: 2006 end-page: 1588 article-title: Outcome of acute idiosyncratic drug‐induced liver injury: long‐term follow‐up in a hepatotoxicity registry publication-title: Hepatology – volume: 15 start-page: 921 year: 2003 end-page: 924 article-title: Autoimmune hepatitis revealed by atorvastatin publication-title: Eur J Gastroenterol Hepatol – volume: 150 start-page: 249 year: 2001 end-page: 254 article-title: Liver fibrosis attributed to lipid lowering medications: two cases publication-title: J Intern Med – volume: 299 start-page: 314 year: 1978 article-title: Possible association of granulomatous hepatitis with clofibrate therapy publication-title: N Engl J Med – volume: 52 start-page: 2065 year: 2010 end-page: 2076 article-title: Drug‐induced acute liver failure: results of a U.S. multicenter, prospective study publication-title: Hepatology – volume: 40 start-page: 757 year: 2006 end-page: 761 article-title: Autoimmune hepatitis triggered by statins publication-title: J Clin Gastroenterol – volume: 57 start-page: 1959 year: 2012 end-page: 1964 article-title: Jaundice Due to Suspected Statin Hepatotoxicity: a Case Series publication-title: Dig Dis Sci – volume: 82 start-page: 233 year: 1991 end-page: 235 article-title: Acute cholestatic hepatitis during simvastatin administration publication-title: Recenti Prog Med – volume: 170 start-page: 2088 year: 1959 end-page: 2089 article-title: Jaundice occurring during nicotinic acid therapy for hypercholesterolemia publication-title: JAMA – volume: 344 start-page: 1383 year: 1994 end-page: 1389 article-title: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) publication-title: Lancet – volume: 105 start-page: 2396 year: 2010 end-page: 2404 article-title: Single‐center experience with drug‐induced liver injury from India: causes, outcome, prognosis, and predictors of mortality publication-title: Am J Gastroenterol – volume: 39 start-page: 1095 year: 2003 end-page: 1097 article-title: Fatal liver failure with atorvastatin publication-title: J Hepatol – volume: 76 start-page: 239 year: 1983 end-page: 241 article-title: Niacin hepatitis publication-title: South Med J – volume: 148 start-page: 1340 year: 2015 end-page: 1352 article-title: Features and outcomes of 899 patients with drug‐induced liver injury: the DILIN prospective study publication-title: Gastroenterology – volume: 106 start-page: 246 year: 2014 end-page: 254 article-title: Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry publication-title: Rev Esp Enferm Dig – volume: 333 start-page: 1301 year: 1995 end-page: 1307 article-title: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group publication-title: N Engl J Med – volume: 51 start-page: 2040 year: 2010 end-page: 2048 article-title: Drug‐induced Autoimmune Hepatitis: clinical characteristics and prognosis publication-title: Hepatology – volume: 58 start-page: 388 year: 2013 end-page: 396 article-title: High lipophilicity and high daily dose of oral medications are associated with significant risk for drug‐induced liver injury publication-title: Hepatology – volume: 151 start-page: 43 year: 1999 end-page: 49 article-title: Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia publication-title: Arch Intern Med – volume: 126 start-page: 1287 year: 2004 end-page: 1292 article-title: Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity publication-title: Gastroenterology – volume: 10 start-page: 1018 year: 2004 end-page: 1023 article-title: Liver transplantation for acute liver failure from drug induced liver injury in the United States publication-title: Liver Transpl – volume: 113 start-page: 348 year: 2002 end-page: 349 article-title: Multiorgan failure induced by atorvastatin publication-title: Am J Med – volume: 228 start-page: 202 year: 1974 article-title: Jaundice following the administration of niacin publication-title: JAMA – volume: 13 start-page: 602 year: 2015 end-page: 608 article-title: The risk of drug‐induced liver injury from Tumor Necrosis Factor (TNF)‐alpha‐antagonists publication-title: Clin Gastroenterol Hepatol – volume: 29 start-page: 412 year: 2009 end-page: 422 article-title: Drug‐induced liver injury associated with statins publication-title: Review. Semin Liver Dis – volume: 60 start-page: 679 year: 2014 end-page: 686 article-title: Spectrum of statin hepatotoxicity: experience of the drug‐induced liver injury network publication-title: Hepatology – volume: 135 start-page: 1924 year: 2008 end-page: 1934 article-title: Causes, clinical features, and outcomes from a prospective study of drug‐induced liver injury in the United States. Drug Induced Liver Injury Network (DILIN) publication-title: Gastroenterology – volume: 37 start-page: S9 issue: Suppl 1 year: 2014 end-page: S17 article-title: Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges publication-title: Drug Saf – volume: 38 start-page: 772 year: 2006 end-page: 777 article-title: Atorvastatin associated liver disease publication-title: Dig Liver Dis – volume: 47 start-page: 2003 year: 2008 end-page: 2009 article-title: Relationship between daily dose of oral medications and idiosyncratic drug‐induced liver injury (DILI): search for signals publication-title: Hepatology – volume: 42 start-page: 481 year: 2005 end-page: 489 article-title: Outcome and prognostic markers in severe drug‐induced liver disease publication-title: Hepatology – volume: 63 start-page: 590 year: 2016 end-page: 603 article-title: Categorization of drugs implicated in causing liver injury: critical assessment based upon published case reports publication-title: Hepatology – volume: 59 start-page: 87 year: 1998 end-page: 88 article-title: Niacin. Help for your cholesterol–harm for your liver publication-title: N C Med J – volume: 46 start-page: 1453 year: 2007 end-page: 1463 article-title: Efficacy and safety of high‐dose pravastatin in hypercholesterolemic patients with well‐compensated chronic liver disease: results of a prospective, randomized, double‐blind, placebo‐controlled, multicenter trial publication-title: Hepatology – volume: 56 start-page: 374 year: 2012 end-page: 380 article-title: Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post‐marketing publication-title: J Hepatol – volume: 155 start-page: 61 year: 1991 article-title: Liver side effects associated with simvastatin therapy publication-title: Med J Aust – volume: 144 start-page: 1419 year: 2013 end-page: 1425 article-title: Incidence, presentation and outcomes in patients with drug‐induced liver injury in the general population of Iceland. incidence, presentation and outcomes in patients with drug‐induced liver injury in the general population of Iceland publication-title: Gastroenterology – volume: 16 start-page: 597 year: 2005 end-page: 599 article-title: Drug‐induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe publication-title: Curr Opin Lipidol – volume: 15 start-page: 94 year: 1991 end-page: 95 article-title: A case of hepatitis caused by simvastatin [French] publication-title: Gastroenterol Clin Biol – volume: 21 start-page: 419 year: 1998 end-page: 420 article-title: Acute hepatitis caused by gemfibrozil publication-title: Gastroenterol Hepatol – ident: e_1_2_11_36_1 doi: 10.1097/00042737-200308000-00014 – ident: e_1_2_11_24_1 doi: 10.1007/s10620-011-1950-1 – ident: e_1_2_11_12_1 doi: 10.1053/j.gastro.2008.09.011 – ident: e_1_2_11_4_1 doi: 10.1001/jama.285.13.1711 – ident: e_1_2_11_35_1 doi: 10.1001/archinte.159.15.1811-a – ident: e_1_2_11_39_1 doi: 10.1016/j.jhep.2010.12.041 – volume: 21 start-page: 419 year: 1998 ident: e_1_2_11_49_1 article-title: Acute hepatitis caused by gemfibrozil publication-title: Gastroenterol Hepatol contributor: fullname: Bustamante Balén M – ident: e_1_2_11_34_1 doi: 10.1016/j.cgh.2014.07.062 – volume: 16 start-page: 597 year: 2005 ident: e_1_2_11_37_1 article-title: Drug‐induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe publication-title: Curr Opin Lipidol contributor: fullname: Heyningen C – volume: 59 start-page: 87 year: 1998 ident: e_1_2_11_47_1 article-title: Niacin. Help for your cholesterol–harm for your liver publication-title: N C Med J contributor: fullname: Rourk RM – ident: e_1_2_11_42_1 doi: 10.1016/S0168-8278(03)00464-1 – ident: e_1_2_11_13_1 doi: 10.1038/ajg.2010.287 – ident: e_1_2_11_10_1 doi: 10.1002/hep.20800 – ident: e_1_2_11_48_1 doi: 10.1046/j.1365-2796.2001.00848.x – volume: 151 start-page: 43 year: 1999 ident: e_1_2_11_3_1 article-title: Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia publication-title: Arch Intern Med doi: 10.1001/archinte.1991.00400010067008 contributor: fullname: Bradford RH – ident: e_1_2_11_25_1 doi: 10.1016/j.amjmed.2005.02.008 – ident: e_1_2_11_23_1 doi: 10.1002/hep.21848 – ident: e_1_2_11_5_1 doi: 10.1056/NEJM199511163332001 – ident: e_1_2_11_45_1 doi: 10.1097/00007611-198302000-00023 – ident: e_1_2_11_14_1 doi: 10.1097/MCG.0b013e3181c5e9cc – ident: e_1_2_11_18_1 doi: 10.1002/hep.23937 – ident: e_1_2_11_43_1 doi: 10.1016/j.dld.2006.04.013 – ident: e_1_2_11_30_1 doi: 10.1002/hep.23317 – ident: e_1_2_11_15_1 doi: 10.1053/j.gastro.2013.02.006 – ident: e_1_2_11_19_1 doi: 10.1016/j.jhep.2011.07.023 – ident: e_1_2_11_51_1 doi: 10.1002/hep.21424 – volume: 15 start-page: 94 year: 1991 ident: e_1_2_11_7_1 article-title: A case of hepatitis caused by simvastatin [French] publication-title: Gastroenterol Clin Biol contributor: fullname: Feydy P – ident: e_1_2_11_44_1 doi: 10.1001/jama.1959.63010170008010c – ident: e_1_2_11_22_1 doi: 10.1053/j.gastro.2004.02.015 – ident: e_1_2_11_26_1 doi: 10.1002/lt.20204 – ident: e_1_2_11_31_1 doi: 10.1016/S0002-9343(02)01178-6 – ident: e_1_2_11_50_1 doi: 10.1056/NEJM197808102990622 – ident: e_1_2_11_29_1 doi: 10.1002/hep.26208 – ident: e_1_2_11_41_1 doi: 10.1002/hep.28323 – ident: e_1_2_11_17_1 doi: 10.1055/s-0029-1240010 – ident: e_1_2_11_28_1 doi: 10.1002/hep.22272 – volume: 82 start-page: 233 year: 1991 ident: e_1_2_11_8_1 article-title: Acute cholestatic hepatitis during simvastatin administration publication-title: Recenti Prog Med contributor: fullname: Ballare M – ident: e_1_2_11_32_1 doi: 10.5694/j.1326-5377.2002.tb04559.x – ident: e_1_2_11_27_1 doi: 10.1016/j.jhep.2014.11.019 – ident: e_1_2_11_21_1 doi: 10.1002/hep.27157 – ident: e_1_2_11_38_1 doi: 10.1097/00004836-200609000-00018 – ident: e_1_2_11_46_1 doi: 10.1001/jama.1974.03230270046027 – ident: e_1_2_11_6_1 doi: 10.1007/s40264-014-0182-7 – ident: e_1_2_11_9_1 doi: 10.5694/j.1326-5377.1991.tb116406.x – ident: e_1_2_11_11_1 doi: 10.1016/j.gastro.2005.05.006 – ident: e_1_2_11_2_1 doi: 10.1016/S0140-6736(94)91755-8 – ident: e_1_2_11_16_1 doi: 10.1053/j.gastro.2015.03.006 – volume: 106 start-page: 246 year: 2014 ident: e_1_2_11_20_1 article-title: Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry publication-title: Rev Esp Enferm Dig contributor: fullname: Perdices EV – ident: e_1_2_11_33_1 doi: 10.1002/hep.23588 – ident: e_1_2_11_40_1 doi: 10.1016/j.jhep.2016.05.003 |
| SSID | ssj0019951 |
| Score | 2.529486 |
| SecondaryResourceType | review_article |
| Snippet | Statins are generally well tolerated and adverse effects are relatively rare. Clinical trials are underpowered to detect uncommon adverse effects such as... Abstract Statins are generally well tolerated and adverse effects are relatively rare. Clinical trials are underpowered to detect uncommon adverse effects such... |
| SourceID | proquest crossref pubmed wiley |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 173 |
| SubjectTerms | Atorvastatin Atorvastatin Calcium - adverse effects Case reports Chemical and Drug Induced Liver Injury - epidemiology Clinical trials Drugs drug‐induced liver injury Hepatotoxicity Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Immunosuppressive agents Injuries Liver Liver transplantation Medical research Patients Side effects Simvastatin Simvastatin - adverse effects Statins Transplantation |
| Title | Hepatotoxicity of statins and other lipid‐lowering agents |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fliv.13308 https://www.ncbi.nlm.nih.gov/pubmed/27860156 https://www.proquest.com/docview/1920516477/abstract/ |
| Volume | 37 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEB5KD-LFR31Fqywi4iUlTbJJSk9FLFXUg1jpQQib3QSKNSkmFevJn-Bv9Jc4u3lgFUG8hZAsyc7OfjO7830LcORgchMYgqEjcVu3hWPpzHM6usUjTy7th22uCmSvncHQvhjRUQ26JRcm14eoFtykZ6j5Wjo4C9IvTj4ZP7cwwVJEXymkJwOim0o6SjKPVbJly-1_xMBCVUhW8VRvLmLRjwBzMV5VgNNfhfvyU_M6k4fWLAta_PWbiuM__2UNVopAlPTykbMOtTBuwEYvxiT8cU6OiSoNVWvuDVi6KnbgN6A7QPzKkix5wRvZnCQRkZykcZwSFgui-FxkMp6Oxcfb-0QewYbYSJgkcKWbMOyf3Z4O9OIABp1bmBnrHnMFWli4eBF6lLnUdSmlATccxHlmhaITGNxjgS2syBAe55EVqZ1QqfrHTGsL6nEShztAsB1hCpO7IXfsSNCOJzBYpIbBedsVrK3BYWkKf5rrbPhlfoK946ve0aBZGskvXC31MUTFiUXyaTXYzg1XtWC6niO54hqcqO7_vWn_8vxOXez-_dE9WDYlyKsa7ibUs6dZuI8hShYcqLH4CQj74aw |
| link.rule.ids | 315,786,790,1382,27957,27958,46329,46753 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NSsNAEB6Kgnrxp_WnWnURES8paZJNUvRSxFK17UFa6UXCZjeBYk2LTcV68hF8Rp_E2U1SrCKIt01IlmRnZ2e-2flmAY5tBDe-LhgqErc0S9imxly7qpk8dGVoP6hwlSDbthtd67pHezk4z7gwSX2IWcBNaoZar6WCy4D0Fy0f9J_LiLAk03cR1Z0qQHU7Kx4luccKblkyAQCtYFpXSObxzF6dt0Y_XMx5j1WZnPoa3Gcfm2SaPJQnsV_mr9_qOP73b9ZhNfVFSS2ZPBuQC6I8FGoR4vDHKTkhKjtUhd3zsNRKN-ELcNZAExYP4-EL3oinZBgSSUvqR2PCIkEUpYsM-qO--Hh7H8hT2NA8EiY5XONN6NYvOxcNLT2DQeMmgmPNZY5AIQsHG4FLmUMdh1Lqc91GU8_MQFR9nbvMt4QZ6sLlPDRDtRkqC_8xw9yChWgYBTtAsB9hCIM7AbetUNCqK9BfpLrOecURrFKEo0wW3igpteFlEAVHx1OjU4RSJiUv1baxh14qri2SUluE7URysx4Mx7UlXbwIp2r8f-_aa17dqcbu3x89hOVGp9XE6_bNHqwY0uarlO4SLMRPk2AfPZbYP1AT8xM34OXO |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEB6KQvHio_VRrbqIiJeUNO_SU7GW-ioiVnoQwmY3gWBNi03FevIn-Bv9Jc5uHlhFEG-bkCzJzs5-M7PzzQIcWujceCqnqEjMUAxu6Qp1rIais8ARoX2_zmSCbM_q9o3zgTkoQDPjwiT1IfKAm9AMuV4LBR_z4IuSD8PnGjpYgui7aFi6JqZ0-yavHSWox9LbMsT-P4JgWlZIpPHkr86D0Q8Lc95glYjTWYH77FuTRJOH2jT2auz1WxnHf_7MKiynlihpJVNnDQp-VIJyK0Iv_HFGjojMDZVB9xIUr9It-DI0uwhg8SgeveCNeEZGARGkpDCaEBpxIgldZBiOQ_7x9j4UZ7AhOBIqGFyTdeh3Tm9Pukp6AoPCdHSNFYfaHEXMbWz4jklt07ZN0_SYaiHQU93nDU9lDvUMrgcqdxgL9EBuhYqyf1TTN2AhGkX-FhDsh2tcY7bPLCPgZsPhaC2aqspY3ea0XoGDTBTuOCm04WYOCo6OK0enAtVMSG6qaxMXbVRcWQShtgKbieDyHjTbsQRZvALHcvh_79q9PLuTje2_P7oPxet2By97FzuwpAnAl_ncVViIn6b-Lporsbcnp-Uno0rkfQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hepatotoxicity+of+statins+and+other+lipid%E2%80%90lowering+agents&rft.jtitle=Liver+international&rft.au=Bj%C3%B6rnsson%2C+Einar+S.&rft.date=2017-02-01&rft.issn=1478-3223&rft.eissn=1478-3231&rft.volume=37&rft.issue=2&rft.spage=173&rft.epage=178&rft_id=info:doi/10.1111%2Fliv.13308&rft.externalDBID=10.1111%252Fliv.13308&rft.externalDocID=LIV13308 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-3223&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-3223&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-3223&client=summon |